Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

Autor: Bethune, Claire, Boffito, Marta, Bula, Marcin, Burns, Fiona M, Clark, Rebecca, Dasyam, Dileep, Drysdale, Simon, Faust, Saul, Gkrania-Klotsas, Effrossyni, Green, Christopher, Hassanin, Hana, Heath, Paul, Heer, Amardeep, Helliwell, Toby, Hormis, Anil, Kalra, Philip, Lazarus, Rajeka, Moran, Ed, Ndikum, John, Page, Iain, Price, David, Probert, Nick, Ramjee, Mahadev, Rampling, Tommy, Randeva, Harpal S, Ryder, Stephen, Steer, John, Thompson, Emma, Torku, David, Querton, Benedicte b, Corbic Ramljak, Irena b, Dewasthaly, Shailesh b, Jaramillo, Juan Carlos b, Dubischar, Katrin b, Krammer, Michael b, Weisova, Petronela b, Hochreiter, Romana b, Eder-Lingelbach, Susanne b, Taucher, Christian b, *, *, Finn, Adam a, c
Zdroj: In The Lancet Infectious Diseases December 2022 22(12):1716-1727
Databáze: ScienceDirect